Key result
Sirolimus-coated balloon PCI shows comparable target lesion failure to DES in diabetic patients.
Why the study?
Does sirolimus-coated balloon-based PCI reduce target lesion failure in diabetic patients with de novo CAD compared to DES-only PCI?
Observational (n=1,838)
Yes
Does sirolimus-coated balloon-based PCI reduce target lesion failure in diabetic patients with de novo CAD compared to DES-only PCI?
In diabetic patients with de novo CAD, an SCB-based PCI strategy showed comparable 2-year clinical outcomes to DES-only PCI, suggesting it may be a safe alternative to reduce metal implantation.
Answers are grounded in this paper and cite their sources.
SCB-based PCI may offer a stent-sparing option in diabetic de novo CAD; leaves open randomized confirmation of long-term outcomes.
Diabetic patients undergoing percutaneous coronary intervention (PCI) frequently have complex coronary artery disease (CAD) and suboptimal outcomes with drug-eluting stents (DES). Sirolimus-coated balloons (SCB) have recently been introduced, but comparative data versus DES in diabetic patients with de novo CAD are lacking. The SIMPLE-DM study is a pooled analysis of five observational registries including all-comer diabetic patients undergoing PCI for de novo CAD. Patients in the SCB cohort were treated with the phospholipid nanocarrier Magic Touch SCB, while those in the DES cohort received current-generation DES. Propensity score (PS) adjustment was used to balance clinical and angiographic characteristics. The primary endpoint was the 2-year cumulative incidence of target lesion failure (TLF), defined as the composite of cardiac death, target vessel MI (TV-MI), or target lesion revascularization (TLR). A total of 1838 patients were included, 599 treated with SCB-based PCI and 1239 with DES-only PCI. At 2 years, TLF occurred in 9.1% of SCB and 9.9% of DES patients (adj. hazard ratio HR 0.88, 95% confidence interval CI 0.43–1.81, p = 0.736). No significant differences were found in cardiac death, TV-MI or TLR. SCB-based PCI was associated with more favourable outcomes in patients with chronic kidney disease ( p for interaction = 0.042) and long lesions ( p for interaction = 0.003), whereas DES-only PCI performed better in those with short lesions. In diabetic patients undergoing PCI for de novo CAD, an SCB-based strategy was associated with comparable 2-year outcomes to DES-only PCI, with signals of potential benefit in the highest clinical and anatomical risk subsets. Abbreviations: ACS, acute coronary syndrome; ASTUTE, Amphilimus Italian multicentre registry; BP, biodegradable-polymer; CCS, chronic coronary syndrome; CKD, chronic kidney disease; DES, drug-eluting stent; EASTBOURNE, All-Comers Sirolimus-Coated Balloon European Registry; HR, hazard ratio; IDDM, insulin-dependent diabetes mellitus; PCI, percutaneous coronary intervention; PF, polymer-free; RUDI-FREE, Polymer-free biolimus-eluting stent implantation in all-comers population; SCB, sirolimus-coated balloon; TLF, target lesion failure; TLR, target lesion revascularization; TVF, target vessel failure; TV-MI, target vessel myocardial infarction; ULISSE, ULtimaster Italian multicenter all comerS Stent rEgistry.
No takes yet. Share an insight, caveat, or question.
Gitto et al. (2026) conducted an observational in Diabetes mellitus with de novo coronary artery disease (n=1,838). Sirolimus-coated balloon-based percutaneous coronary intervention vs. Drug-eluting stent-only percutaneous coronary intervention was evaluated on 2-year cumulative incidence of target lesion failure (composite of cardiac death, target vessel MI, or target lesion revascularization) (HR 0.88, 95% CI 0.43-1.81, p=0.736). Sirolimus-coated balloon-based percutaneous coronary intervention was associated with a comparable 2-year rate of target lesion failure compared to drug-eluting stent-only intervention in diabetic patients with de novo coronary artery disease.
Synapse has enriched 10 related papers. Consider them for comparative context: